Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Xcel Energy Inc — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.73 (market cap $58.74B), while Xcel Energy Inc trades at $73.78 (market cap $45.82B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days and Xcel Energy Inc for 61 Days on average.
| TAK | XEL | |
|---|---|---|
Market Cap | $58.74B | $45.82B |
Volume | 3,110,994 | 6,910,516 |
Sector | Health | Utilities |
52-Week High | $19.05 | $83.91 |
52-Week Low | $13.23 | $69.39 |
Typical Hold Time | 1 Days | 61 Days |
Enterprise Value | $86.65B | $84.14B |
Dividend Yield | 3.33% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Xcel Energy (XEL) trades at $73.36, up 1.3% with bullish technical signals and strong institutional support. The stock shows solid fundamentals with $14.67B revenue, 15.28% net margin, and consistent earnings beats. Recent news highlights growth from data center power demand and a $60B capital investment plan. Technical indicators show bullish momentum with support at $72-73 and resistance at $74-75 levels.
XEL presents a compelling investment case with analyst consensus target of $90.83 (24% upside) and 63% buy ratings. Key opportunities include infrastructure expansion and rising power demand, while risks involve wildfire liabilities and high capital expenditure. The stock's valuation at 20.1 P/E appears reasonable given growth prospects and dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
